Kazuto Nishio
#198,218
Most Influential Person Across History
Researcher
Kazuto Nishio's AcademicInfluence.com Rankings
Kazuto Nishiocomputer-science Degrees
Computer Science
#8669
Historical Rank
Computational Linguistics
#1818
Historical Rank
Machine Learning
#3365
Historical Rank
Artificial Intelligence
#3678
Historical Rank
Download Badge
Computer Science
Kazuto Nishio's Degrees
- PhD Computer Science University of Tokyo
- Masters Computer Science University of Tokyo
- Bachelors Computer Science University of Tokyo
Similar Degrees You Can Earn
Why Is Kazuto Nishio Influential?
(Suggest an Edit or Addition)Kazuto Nishio's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab (2011) (577)
- Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. (2003) (554)
- LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. (2013) (325)
- Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer (2006) (288)
- Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. (1991) (273)
- Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor (2007) (237)
- Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment (2017) (229)
- Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA) (2007) (208)
- Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer (2012) (205)
- FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. (2010) (167)
- FGFR2 gene amplification and clinicopathological features in gastric cancer (2012) (164)
- Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer (2011) (162)
- EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs (2015) (160)
- FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. (2011) (152)
- Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients (2006) (151)
- Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7, breast cancer cells. (1999) (149)
- mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. (2009) (149)
- RPN2 gene confers docetaxel resistance in breast cancer (2008) (148)
- FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma (2013) (143)
- Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer (2012) (141)
- Establishment of a human non‐small cell lung cancer cell line resistant to gefitinib (2005) (137)
- AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over-Expressing Fibroblast Growth Factor Receptor 2/Keratinocyte Growth Factor Receptor (2007) (136)
- High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non‐small cell lung cancer patients (2006) (134)
- Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer (2011) (131)
- Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors (2011) (126)
- Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma (2011) (120)
- Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation (2012) (118)
- Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (“Iressa”) and the DNA topoisomerase I inhibitor CPT‐11 (irinotecan) in human colorectal cancer cells (2004) (116)
- Emerging ethnic differences in lung cancer therapy (2008) (115)
- EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib (2006) (115)
- Small In-Frame Deletion in the Epidermal Growth Factor Receptor as a Target for ZD6474 (2004) (113)
- The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer (2013) (112)
- Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. (2007) (112)
- Identification of expressed genes characterizing long-term survival in malignant glioma patients (2006) (110)
- Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer (2005) (109)
- Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. (2007) (109)
- Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. (1992) (107)
- Effects of β- and γ-carboline derivatives on DNA topoisomerase activities (1996) (104)
- Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer (2014) (102)
- Mechanisms of Action of the Novel Sulfonamide Anticancer Agent E7070 on Cell Cycle Progression in Human Non-Small Cell Lung Cancer Cells (2004) (101)
- EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line (2008) (98)
- Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3 (2011) (94)
- Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors (2010) (91)
- Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway (2007) (91)
- An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. (2012) (91)
- Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. (1992) (90)
- Tocilizumab, a Proposed Therapy for the Cachexia of Interleukin6-Expressing Lung Cancer (2014) (89)
- MET amplification as a potential therapeutic target in gastric cancer (2012) (89)
- Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cell. (2007) (89)
- DS‐8201a, a new HER2‐targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2‐positive gastric cancer T‐DM1 resistance (2017) (89)
- Antitumor activity of the selective epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) Iressa® (ZD1839) in an EGFR‐expressing multidrug‐resistant cell line in vitro and in vivo (2002) (89)
- B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity (2018) (88)
- A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer (2008) (88)
- Targeting MET Amplification as a New Oncogenic Driver (2014) (88)
- N-myc downstream regulated gene 1/Cap43 suppresses tumor growth and angiogenesis of pancreatic cancer through attenuation of inhibitor of kappaB kinase beta expression. (2009) (88)
- The MRP family and anticancer drug metabolism. (2001) (87)
- Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. (2005) (87)
- Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples (2008) (87)
- Osteopontin induces angiogenesis of murine neuroblastoma cells in mice (2002) (85)
- Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. (2010) (84)
- TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non–Small Cell Lung Cancer with an EGFR Mutation (2010) (82)
- Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. (1991) (81)
- Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients (2016) (81)
- Differential osteopontin expression in lung cancer. (2001) (80)
- Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non–Small Cell Lung Adenocarcinoma (2010) (79)
- Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase–Targeted Agents in Non–Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor (2010) (79)
- Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shortened survival in syngeneic mice. (1993) (77)
- Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. (2008) (77)
- Prognostic implications of the nuclear localization of Y‐box‐binding protein‐1 and CXCR4 expression in ovarian cancer: Their correlation with activated Akt, LRP/MVP and P‐glycoprotein expression (2007) (76)
- Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer (2011) (76)
- Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification (2012) (76)
- Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor? (2016) (74)
- Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor (2013) (74)
- Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site. (2019) (74)
- Gamma-glutamylcysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance. (1995) (73)
- Characterization of a Taxol‐resistant Human Small‐cell Lung Cancer Cell Line (1994) (73)
- Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer (2015) (73)
- EGFR Mutation of Tumor and Serum in Gefitinib-Treated Patients with Chemotherapy-Naive Non–small Cell Lung Cancer (2006) (71)
- Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. (2003) (71)
- Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib (2016) (71)
- SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion (2009) (70)
- Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification (2011) (70)
- De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer (2010) (70)
- Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma (2013) (70)
- Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples (2015) (69)
- Hypoxia induces gefitinib resistance in non‐small‐cell lung cancer with both mutant and wild‐type epidermal growth factor receptors (2012) (68)
- Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations (2016) (68)
- Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study (2015) (68)
- Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib‐resistant non‐small cell lung cancer cells with acquired MET amplification (2010) (67)
- Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer. (2015) (67)
- Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. (2015) (67)
- Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines. (1993) (66)
- Detection of the T790M mutation of EGFR in plasma of advanced non–small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study) (2016) (65)
- Increased cytotoxic effects of photodynamic therapy in IL‐6 gene transfected cells via enhanced apoptosis (2001) (64)
- Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells (2012) (63)
- Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (“Iressa”)‐sensitive and resistant xenograft models (2004) (63)
- Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy (2010) (61)
- TGF-β induces sustained upregulation of SNAI1 and SNAI2 through Smad and non-Smad pathways in a human corneal epithelial cell line. (2011) (60)
- In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. (2001) (60)
- Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. (1992) (60)
- N‐Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor (2008) (60)
- Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer (2016) (59)
- Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III (2008) (59)
- The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells (2014) (59)
- Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer (2007) (58)
- Personalized medicine and proteomics: lessons from non-small cell lung cancer. (2007) (57)
- Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines. (1996) (57)
- Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production (2013) (56)
- An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC (2018) (54)
- Element array by scanning X-ray fluorescence microscopy after cis-diamminedichloro-platinum(II) treatment. (2005) (54)
- Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G (2016) (54)
- Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells. (2001) (52)
- Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells (2012) (52)
- A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination. (2006) (52)
- Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure. (2011) (52)
- Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition (2010) (52)
- Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with MET Amplification (2009) (51)
- Increased expression of the MRP5 gene is associated with exposure to platinum drugs in lung cancer (2000) (51)
- Antitumor activity of TZT‐1027 (Soblidotin) against vascular endothelial growth factor‐secreting human lung cancer in vivo (2003) (51)
- SOX4 is a direct target gene of FRA-2 and induces expression of HDAC8 in adult T-cell leukemia/lymphoma. (2013) (50)
- HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer (2015) (50)
- Drug resistance in lung cancer. (1999) (49)
- 1 alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. (1996) (49)
- Role of ZNF143 in tumor growth through transcriptional regulation of DNA replication and cell‐cycle‐associated genes (2010) (49)
- Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk (2007) (49)
- Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition (2010) (48)
- The Mechanism of the Difference in Cellular Uptake of Platinum Derivatives in Non‐small Cell Lung Cancer Cell Line (PC‐14) and Its Cisplatin‐resistant Subline (PC‐14/CDDP) (1993) (48)
- Dimerization and the signal transduction pathway of a smallin‐frame deletion in the epidermal growth factor receptor (2006) (48)
- Abrogation of the interaction between osteopontin and αvβ3 integrin reduces tumor growth of human lung cancer cells in mice (2007) (47)
- Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition (2014) (46)
- Differential gene expression profile between PC-14 cells treated with free cisplatin and cisplatin-incorporated polymeric micelles. (2003) (46)
- Chemical constituents of a marine fungus, Arthrinium sacchari. (2011) (45)
- Ciliated muconodular papillary tumors of the lung with KRAS/BRAF/AKT1 mutation (2017) (45)
- Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer. (2014) (44)
- The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer (2015) (43)
- Inhibition of &bgr;-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation (2015) (43)
- Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB. (1995) (42)
- Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel (2009) (42)
- Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer. (2015) (41)
- Plasma concentrations of VCAM‐1 and PAI‐1: A predictive biomarker for post‐operative recurrence in colorectal cancer (2010) (41)
- cDNA cloning of a short type of multidrug resistance protein homologue, SMRP, from a human lung cancer cell line. (1997) (40)
- ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model (2006) (40)
- Reversal of Cisplatin Resistance with Amphotericin B in a Non‐small Cell Lung Cancer Cell Line (1991) (39)
- Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy. (2011) (39)
- Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice. (2007) (39)
- Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing (2015) (39)
- Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma (2014) (38)
- Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non‐small cell lung cancer (2008) (38)
- Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial. (2020) (37)
- Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. (2012) (37)
- Intracellular Carboxyl Esterase Activity Is a Determinant of Cellular Sensitivity to the Antineoplastic Agent KW‐2189 in Cell Lines Resistant to Cisplatin and CPT‐11 (1995) (37)
- Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo (2010) (37)
- Clinical practice guidance for next‐generation sequencing in cancer diagnosis and treatment (Edition 1.0) (2018) (36)
- Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib (2016) (36)
- HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer (2018) (36)
- Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib (2014) (35)
- Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer. (2016) (35)
- Tumor volume determines the feasibility of cell‐free DNA sequencing for mutation detection in non‐small cell lung cancer (2016) (35)
- KIAA1199 interacts with glycogen phosphorylase kinase β-subunit (PHKB) to promote glycogen breakdown and cancer cell survival (2014) (35)
- A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer (2009) (34)
- SRPX2 Is a Novel Chondroitin Sulfate Proteoglycan That Is Overexpressed in Gastrointestinal Cancer (2012) (34)
- Antiangiogenic metabolites from a marine-derived fungus, Hypocrea vinosa. (2010) (34)
- Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment (2016) (34)
- Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis. (2015) (34)
- Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody (2021) (34)
- Enhancement of Sensitivity to Tumor Necrosis Factor α in Non–Small Cell Lung Cancer Cells with Acquired Resistance to Gefitinib (2005) (33)
- Enhancement of Cisplatin Sensitivity in High Mobility Group 2 cDNA‐transfected Human Lung Cancer Cells (1999) (32)
- Multiplex genomic profiling of non–small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study (2014) (32)
- Mechanism of action of aragusterol a (YTA0040), a potent anti‐tumor marine steroid targeting the G1 phase of the cell cycle (2000) (32)
- Acquired drug resistance to vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor in human vascular endothelial cells. (2011) (32)
- A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. (2018) (32)
- Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1) (2020) (32)
- Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells (2011) (31)
- FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib (2016) (31)
- EGFR mutation up-regulates EGR1 expression through the ERK pathway. (2009) (31)
- Slug is upregulated during wound healing and regulates cellular phenotypes in corneal epithelial cells. (2012) (31)
- Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines (2014) (30)
- N-myc Downstream Regulated Gene 1 (NDRG1) Promotes Metastasis of Human Scirrhous Gastric Cancer Cells through Epithelial Mesenchymal Transition (2012) (30)
- Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor in lung cancer (2016) (30)
- Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion. (2019) (30)
- Identification ofcis-Acting DNA Elements of the Human γ-Glutamylcysteine Synthetase Heavy Subunit Gene (1997) (30)
- Preferential Binding of E7010 to Murine β3‐Tubulin and Decreased β3‐Tubulin in E7010‐resistant Cell Lines (1998) (30)
- Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal. (2015) (30)
- MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor. (2015) (29)
- EGRI and FOSB gene expressions in cancer stroma are independent prognostic indicators for epithelial ovarian cancer receiving standard therapy (2012) (29)
- A Novel Antitumor Antibiotic, KW‐2189 Is Activated by Carboxyl Esterase and Induces DNA Strand Breaks in Human Small Cell Lung Cancer Cells (1994) (29)
- Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A (2017) (29)
- U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. (2019) (29)
- Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells (2004) (29)
- Overexpression of heparan sulfate 6-O-sulfotransferase-2 in colorectal cancer (2013) (28)
- Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing (2019) (28)
- Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer (2014) (27)
- Interferon‐γ‐inducing Factor Gene Transfection into Lewis Lung Carcinoma Cells Reduces Tumorigenicity in vivo (1997) (27)
- Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients. (2012) (27)
- Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma (2013) (27)
- Identification of predictive biomarkers for response to trastuzumab using plasma FUCA activity and N-glycan identified by MALDI-TOF-MS. (2009) (27)
- A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G). (2011) (27)
- Strategy for the development of novel anticancer drugs (2003) (27)
- Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision‐Making for Patients with Advanced Solid Tumors (2020) (27)
- Mitogen‐activated protein kinase phosphatase‐1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor‐tyrosine kinase (2009) (26)
- Detailed structural analysis on both human MRP5 and mouse mrp5 transcripts. (2000) (26)
- Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phena nthridini um hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines. (1997) (26)
- Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions (2014) (26)
- Enhanced expression of nuclear factor I/B in oxaliplatin‐resistant human cancer cell lines (2011) (26)
- Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines. (2002) (25)
- The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells (2017) (25)
- The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile (2013) (24)
- A Literature Review of Molecular Markers Predictive of Clinical Response to Cytotoxic Chemotherapy in Patients with Lung Cancer (2006) (24)
- Potential anti-angiogenesis effects of p-terphenyl compounds from Polyozellus multiplex. (2014) (24)
- Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer (2018) (24)
- Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients. (2011) (24)
- KDR Kinase Inhibitor Isolated from the Mushroom Boletopsis leucomelas. (2010) (24)
- Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR. (2006) (24)
- Reversal of multidrug resistance by tyrosine‐kinase inhibitors in a non‐P‐glycoprotein‐mediated multidrug‐resistant cell line (1994) (23)
- Slug increases sensitivity to tubulin-binding agents via the downregulation of βIII and βIVa-tubulin in lung cancer cells (2013) (23)
- Exploration of resistance mechanisms for epidermal growth factor receptor‐tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next‐generation sequencing (2018) (23)
- Osteopontin modulates malignant pleural mesothelioma cell functions in vitro. (2009) (22)
- Plasma concentrations of angiogenesis-related molecules in patients with pancreatic cancer. (2012) (22)
- Effect of suramin on p34cdc2 kinase in vitro and in extracts from human H69 cells: evidence for a double mechanism of action. (1994) (22)
- Characterisation of a vindesine-resistant human small-cell lung cancer cell line. (1993) (22)
- KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms (2021) (22)
- Development of On-Chip Multi-Imaging Flow Cytometry for Identification of Imaging Biomarkers of Clustered Circulating Tumor Cells (2014) (22)
- Phospholipase C-mediated hydrolysis of phosphatidylcholine is activated by cis-diamminedichloroplatinum(II). (1992) (22)
- Genistein, a Tyrosine Kinase Inhibitor, Decreased the Affinity of p56lck to β-Chain of Interleukin-2 Receptor in Human Natural Killer (NK)-Rich Cells and Decreased NK-Mediated Cytotoxicity (1994) (22)
- Characterization of an etoposide-resistant human small-cell lung cancer cell line (2008) (22)
- p16INK4 Expression Is Associated with the Increased Sensitivity of Human Non‐small Cell Lung Cancer Cells to DNA Topoisomerase I Inhibitors (1997) (21)
- Clinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement. (2012) (21)
- Establishment of a CPT-11-resistant human ovarian cancer cell line. (1994) (21)
- Upregulated expression of angiogenesis genes and down regulation of cell cycle genes in human colorectal cancer tissue determined by cDNA macroarray. (2001) (21)
- Up-regulated gene expression of angiogenesis factors in post-chemotherapeutic lung cancer tissues determined by cDNA macroarray. (2002) (21)
- Cross-resistance to tumour promoters in human cancer cell lines resistant to adriamycin or cisplatin. (1990) (21)
- An in vivo highly antitumor-active tetrazolato-bridged dinuclear platinum(II) complex largely circumvents in vitro cisplatin resistance: two linkage isomers yield the same product upon reaction with 9-ethylguanine but exhibit different cytotoxic profiles. (2012) (21)
- Significance of FGF9 gene in resistance to anti‐EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti‐EGFR therapies (2017) (21)
- Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells (1999) (20)
- Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1 (2020) (20)
- Integrated analysis of whole genome exon array and array‐comparative genomic hybridization in gastric and colorectal cancer cells (2012) (20)
- MEK inhibitors against MET-amplified non-small cell lung cancer (2016) (20)
- Novel Single Nucleotide Polymorphism Markers for Low Dose Aspirin-Associated Small Bowel Bleeding (2013) (20)
- Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts (2020) (20)
- Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer (2014) (20)
- Mechanism of vinorelbine-induced radiosensitization of human small cell lung cancer cells (2002) (20)
- Clinical aspects of epidermal growth factor receptor inhibitors: Benefit and risk (2006) (20)
- Clinical and immune profiling for cancer of unknown primary site (2019) (20)
- Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II–IIIA Non–Small Cell Lung Cancer (2015) (19)
- Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms (2017) (19)
- Longitudinal monitoring of somatic genetic alterations in circulating cell‐free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitors (2019) (19)
- Enhanced Anti‐tumor Effect of Trastuzumab in Combination with Cisplatin (2002) (19)
- Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study (2018) (19)
- Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib. (2005) (19)
- Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors (2012) (19)
- A Microarray-Based Gene Expression Analysis to Identify Diagnostic Biomarkers for Unknown Primary Cancer (2013) (19)
- Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2 (2018) (19)
- Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy. (2019) (19)
- Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib (2015) (19)
- Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer (2016) (19)
- A Novel Mass Spectrometry–Based Assay for Diagnosis of EML4-ALK–Positive Non–Small Cell Lung Cancer (2012) (19)
- A Topoisomerase II Inhibitor, NK109, Induces DNA Single‐ and Double‐strand Breaks and Apoptosis (1996) (19)
- A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors (2013) (18)
- Clinicopathological and genetic differences between low‐grade and high‐grade colorectal mucinous adenocarcinomas (2015) (18)
- CIS‐diamminedichloroplatinum(II) inhibits p34cdc2 protein kinase in human lung‐cancer cells (1993) (18)
- Establishment of a human leukemia subline resistant to the growth‐inhibitory effect of 12‐o‐tetradecanoylphorbol 13‐acetate (TPA) and showing non‐P‐glycoprotein‐mediated multi‐drug resistance (1991) (18)
- Melanoma Transition Is Frequently Accompanied by a Loss of Cytoglobin Expression in Melanocytes: A Novel Expression Site of Cytoglobin (2014) (18)
- Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study (2020) (18)
- Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer (2014) (18)
- Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course. (2019) (18)
- Impact of Tight Junction Protein ZO-1 and TWIST Expression on Postoperative Survival of Patients with Hepatocellular Carcinoma (2016) (18)
- Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status. (2017) (18)
- Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer. (2000) (18)
- Role of multidrug resistance-associated protein 1 in the pathogenesis of allergic airway inflammation. (2009) (18)
- Ouabain‐resistant non‐small‐cell lung‐cancer CELL LINE SHOWS COLLATERAL SENSITIVITY TO cis‐diamminedichloroplatinum(II) (CDDP) (1994) (17)
- MEK Inhibitor for Gastric Cancer with MEK1 Gene Mutations (2014) (17)
- Multiplex gene‐panel testing for lung cancer patients (2020) (17)
- In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib. (2006) (17)
- Gene therapy for Lewis lung carcinoma with tumor necrosis factor and interleukin 2 cDNAs co-transfected subline. (1994) (17)
- Single nucleotide polymorphism markers for low‐dose aspirin‐associated peptic ulcer and ulcer bleeding (2014) (17)
- AZD 2171 Shows Potent AntitumorActivityAgainst Gastric Cancer OverExpressing Fibroblast Growth Factor Receptor 2 / Keratinocyte Growth Factor Receptor (2007) (17)
- Expression of BAF57 in ovarian cancer cells and drug sensitivity (2015) (17)
- Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2 (2016) (17)
- Phase I dose escalation study and biomarker analysis of E7080 in patients with advanced solid tumors (2008) (17)
- New Era for Next-Generation Sequencing in Japan (2019) (17)
- Genes regulating the sensitivity of solid tumor cell lines to cytotoxic agents: a literature review. (2007) (16)
- Characterization of a Human Small‐cell Lung Cancer Cell Line Resistant to a New Water‐soluble Camptothecin Derivative, DX‐8951f (1998) (16)
- Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors (2012) (16)
- Differential gene expression profiles and identification of the genes relevant to clinicopathologic factors in colorectal cancer selected by cDNA array method in combination with principal component analysis. (2003) (16)
- Gene amplification of ribosomal protein S6 kinase-1 and -2 in gastric cancer. (2013) (16)
- Epidermal growth factor receptor lacking C‐terminal autophosphorylation sites retains signal transduction and high sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor (2009) (16)
- Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC (2016) (16)
- Mitogen-activated protein kinase antisense oligonucleotide inhibits the growth of human lung cancer cells. (1999) (16)
- Enhanced antitumor activities of TZT-1027 against TNF-α or IL-6 secreting Lewis lung carcinoma in vivo (2001) (15)
- Developments for a growing Japanese patient population: facilitating new technologies for future health care. (2011) (15)
- Amplification of GNAS may be an independent, qualitative, and reproducible biomarker to predict progression-free survival in epithelial ovarian cancer. (2010) (15)
- Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA. (2019) (15)
- Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion. (2015) (15)
- Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events. (2019) (15)
- EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition. (2015) (15)
- EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation (2013) (15)
- An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. (2012) (15)
- Phase I trial of OTS11101, an anti‐angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor (2013) (14)
- A Randomized Phase II Study Comparing Nivolumab With Carboplatin‐Pemetrexed for Patients With EGFR Mutation–Positive Nonsquamous Non–Small‐Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Stud (2017) (14)
- Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. (2017) (14)
- Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression (2016) (14)
- Problems in the development of target-based drugs (2000) (14)
- Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer (2015) (14)
- The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma (2011) (14)
- Proximal 5'-flanking sequence of the human gamma-glutamylcysteine synthetase heavy subunit gene is involved in cisplatin-induced transcriptional up-regulation in a lung cancer cell line SBC-3. (1997) (14)
- Antitumor action of the PKC activator gnidimacrin through cdk2 inhibition (2001) (13)
- Detection of the T 790 M mutation of EGFR in plasma of advanced non – small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors ( West Japan oncology group 8014 LTR study ) (2016) (13)
- Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer (2015) (13)
- Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells (2017) (13)
- HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer (2021) (13)
- Reversal of adriamycin resistance with chimeric anti‐ganglioside GM2 antibody (1996) (13)
- Serpina3n, Dominantly Expressed in Female Osteoblasts, Suppresses the Phenotypes of Differentiated Osteoblasts in Mice. (2018) (13)
- An early event of EGFR mutation in pleomorphic carcinoma of the lung (2011) (12)
- Establishment and molecular profiling of a novel human pancreatic cancer panel for 5‐FU (2008) (12)
- Gene Expression Profiling of Exposure to TZT-1027, a Novel Microtubule-Interfering Agent, in Non-Small Cell Lung Cancer PC-14 Cells and Astrocytes (2004) (12)
- Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients (2005) (12)
- In vitro and in vivo Effects of Cisplatin and Etoposide in Combination on Small Cell Lung Cancer Cell Lines (1994) (12)
- Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M–positive non–small cell lung cancer: West Japan Oncology Group 8815L/LPS study (2020) (12)
- Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer. (2015) (12)
- Collateral Chemoresistance to Anti-Microtubule Agents in a Lung Cancer Cell Line with Acquired Resistance to Erlotinib (2015) (12)
- Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by Chemoradiotherapy (2015) (12)
- A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing (2019) (12)
- In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant (2005) (12)
- Prospective replication study implicates the catechol-O-methyltransferase Val158Met polymorphism as a biomarker for the response to morphine in patients with cancer. (2017) (12)
- HOXA10 expression profiling in prostate cancer (2019) (11)
- Performance of Oncomine Fusion Transcript kit for formalin‐fixed, paraffin‐embedded lung cancer specimens (2019) (11)
- Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact (2020) (11)
- Epidermolysis bullosa simplex with mottled pigmentation with noncicatricial alopecia: identification of a recurrent p.P25L mutation in KRT5 in four affected family members (2016) (11)
- RASGRP2 Suppresses Apoptosis via Inhibition of ROS Production in Vascular Endothelial Cells (2019) (11)
- Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP-Seq in neoadjuvant chemotherapy-treated advanced ovarian cancer (2020) (11)
- Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression. (2012) (11)
- Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA (2021) (11)
- Genetic profile of adult T‐cell leukemia/lymphoma in Okinawa: Association with prognosis, ethnicity, and HTLV‐1 strains (2021) (11)
- Translational and clinical studies of target-based cancer therapy (2003) (11)
- Loss of genomic DNA copy numbers in the p18, p16, p27 and RB loci in blastic plasmacytoid dendritic cell neoplasm. (2012) (11)
- Ectopic p16ink4 expression enhances CPT‐11‐induced apoptosis through increased delay in S‐phase progression in human non‐small‐cell‐lung‐cancer cells (2000) (11)
- Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy‐induced colitis (2021) (11)
- Expectation of a Decrease in Pain Affects the Prognosis of Pain in Cancer Patients: a Prospective Cohort Study of Response to Morphine (2017) (11)
- Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis. (2021) (11)
- In vitro effects of combinations of cis-amminedichloro (2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line. (2003) (11)
- Bioinformatics Analysis of Gut Microbiota and CNS Transcriptome in Virus-Induced Acute Myelitis and Chronic Inflammatory Demyelination; Potential Association of Distinct Bacteria With CNS IgA Upregulation (2020) (10)
- Alteration of Type II Regulatory Subunit of cAMP‐dependent Protein Kinase in Human Cisplatin‐resistant Cells as a Basis of Collateral Sensitivity to 8‐Chloro‐cAMP (1992) (10)
- Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer (2015) (10)
- Circumvention of glutathione‐mediated mitomycin C resistance by a novel mitomycin C analogue, KW‐2149 (1997) (10)
- A phase II study of gefitinib monotherapy for chemotherapy-naive patients with non-small cell lung cancer (2005) (10)
- Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer (2020) (10)
- Growth Stimulation of Non–Small Cell Lung Cancer Cell Lines by Antibody against Epidermal Growth Factor Receptor Promoting Formation of ErbB2/ErbB3 Heterodimers (2007) (10)
- EphA 4 promotes cell proliferation and migration through a novel EphA 4-FGFR 1 signaling pathway in the human glioma U 251 cell line (2008) (10)
- Influence of novel supramolecular substance, [2] rotaxane, on the caspase signaling pathway in melanoma and colon cancer cells in vitro. (2013) (10)
- Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget’s disease (2016) (10)
- Ectopic p16(ink4) expression enhances CPT-11-induced apoptosis through increased delay in S-phase progression in human non-small-cell-lung-cancer cells. (2000) (10)
- Effect of Glutathione Depletion on Cisplatin Resistance in Cancer Cells Transfected with the γ‐Glutamylcysteine Synthetase Gene (1997) (10)
- In vitro interactions of a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional model (1999) (10)
- Mechanisms of Action of Cancer Chemotherapeutic Agents: Topoisomerase Inhibitors (2005) (10)
- Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence (2014) (10)
- Slug Increases Sensitivity To Tubulin Binding Agents Via The Downregulation Of Beta III And IVa-Tubulin In Lung Cancer Cells (2012) (10)
- An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer. (2015) (10)
- A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer (2015) (10)
- Apoptosis induced by etoposide in small-cell lung cancer cell lines (2004) (10)
- Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study) (2017) (9)
- Characterization of an etoposide-resistant human ovarian cancer cell line (2004) (9)
- Identification of a FGFR3-TACC3 fusion in esophageal cancer. (2016) (9)
- Utilization of arsenic trioxide as a treatment of cisplatin-resistant non-small cell lung cancer PC-9/CDDP and PC-14/CDDP cells. (2015) (9)
- Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG‐TR) (2020) (9)
- A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L) (2021) (9)
- Restoration of p53 gene function in 12-O-tetradecanoylphorbor 13-acetate-resistant human leukemia K562/TPA cells. (2003) (9)
- Gefitinib efficacy associated with multiple expression of HER family in non-small cell lung cancer. (2006) (9)
- Conditional PTEN-deficient mice as a prostate cancer chemoprevention model. (2015) (9)
- Guidance for peptide vaccines for the treatment of cancer (2014) (8)
- Guidelines for clinical evaluation of anti‐cancer drugs (2021) (8)
- The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine (2021) (8)
- The H3K27 demethylase, Utx, regulates adipogenesis in a differentiation stage-dependent manner (2017) (8)
- Translational studies for target-based drugs (2005) (8)
- Mucosal microbiota and gene expression are associated with long-term remission after discontinuation of adalimumab in ulcerative colitis (2020) (8)
- In vitro Enhancement of Antitumor Activity of a Water‐soluble Duocarmycin Derivative, KW‐2189, by Caffeine‐mediated DNA‐repair Inhibition in Human Lung Cancer Cells (1997) (8)
- Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib (2020) (8)
- Abstract 5: Frequency of FGFR2 gene amplification in gastric cancer (2012) (8)
- Reference profiling of the genomic response induced by an antimicrotubule agent, TZT-1027 (Soblidotin), in vitro (2006) (8)
- The C-terminal domain of p53 catalyzes DNA-renaturation and strand exchange toward annealing between intact ssDNAs and toward eliminating damaged ssDNA from duplex formation through preferential recognition of damaged DNA by a duocarmycin. (1998) (7)
- Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor. (2018) (7)
- NivoCUP: An open-label phase II study on the efficacy of nivolumab in cancer of unknown primary. (2020) (7)
- A comprehensive gene mutation analysis of liquid biopsy samples from patients with metastatic colorectal cancer to the ovary: A case report (2018) (7)
- A Case of Metastatic Malignant Breast Adenomyoepithelioma With a Codon-61 Mutation of HRAS. (2019) (7)
- Guidance for ALK Gene Testing in Lung Cancer Patients (2012) (7)
- Detection of Proteins that Recognize Platinum‐modified DNA Using Gel Mobility Shift Assay (1990) (7)
- Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients (2019) (7)
- Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation. (2016) (7)
- Cytoskeletons and antimitotic agents developed in Japan. (1999) (7)
- New strategies for cancer therapy in the 21st century (2001) (7)
- Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer (2021) (7)
- Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis (2021) (7)
- Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI (2019) (7)
- Biomarker study for trastuzumab continuation beyond progression in a randomized phase II trial of weekly paclitaxel±trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum (WJOG7112G). (2018) (7)
- Identification of cis-acting DNA elements of the human gamma-glutamylcysteine synthetase heavy subunit gene. (1997) (7)
- Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L) (2020) (7)
- 1243 Phase I dose-escalation study of continuous oral treatment with the angiokinase inhibitor BIBF 1120 in patients with advanced solid tumors (2009) (6)
- P2-290: Phase II study of S-1 in non-small cell lung cancer (NSCLC) patients previously treated with a platinum-based regimen (2007) (6)
- Characterization of the cytotoxic activity of [2]rotaxane (TRO-A0001), a novel supramolecular compound, in cancer cells (2016) (6)
- hnRNP L enhances sensitivity of the cells to KW‐2189 (2004) (6)
- Fc g R 2 A and 3 A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER 2-positive breast cancer (2011) (6)
- Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer. (2020) (6)
- Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter (2014) (6)
- Phase II study of erlotinib plus tivantinib in patients with EGFR-mutation–positive NSCLC who failed in immediately previous EGFR-TKI therapy. (2014) (6)
- In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice (2004) (6)
- Molecular Cancer Therapeutics Identification of cSrc as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to cSrc Inhibition (2010) (6)
- CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M–positive lung cancer after osimertinib (2021) (6)
- A case of ALK-rearranged non–small cell lung cancer that responded to ceritinib after development of resistance to alectinib (2018) (6)
- Mechanisms of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small lung cancer cell line. (1992) (6)
- Serum Heparan Sulfate Concentration is Correlated with the Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients with Lung Adenocarcinoma (2011) (6)
- Low-Dose Aspirin-Associated Upper and Mid Gastrointestinal Tract Damage and Gene Polymorphism. (2015) (6)
- A Computational Model for Quantitative Analysis of Cell Cycle Arrest and Its Contribution to Overall Growth Inhibition by Anticancer Agents (2000) (6)
- Curcumin β-D-Glucuronide Modulates an Autoimmune Model of Multiple Sclerosis with Altered Gut Microbiota in the Ileum and Feces (2021) (5)
- Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report (2020) (5)
- [Molecular targeted therapies]. (2010) (5)
- Final results of adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis. (2022) (5)
- Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors (2019) (5)
- Increased expression levels of p53 correlate with good response to cisplatin-based chemotherapy in non-small cell lung cancer. (2000) (5)
- Overexpression of CD55 from Barrett's esophagus is associated with esophageal adenocarcinoma risk (2016) (5)
- Decreased Expression of α2,8 Sialyltransferase and Increased Expression of β1,4 N-Acetylgalactosaminyltransferase in Gastrointestinal Cancers (2002) (5)
- A novel malignant peritoneal mesothelioma with STRN exon 2 and ALK exon 20 : a case report and literature review. (2021) (5)
- In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines (2004) (5)
- Human Lung Cancer Cell Lines (1995) (5)
- Differential roles of STAT 3 depending on the mechanism of STAT 3 activation in gastric cancer cells (2014) (4)
- Transcriptome Profiling and Metagenomic Analysis Help to Elucidate Interactions in an Inflammation-Associated Cancer Mouse Model (2021) (4)
- Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs. (2019) (4)
- The anti-HER 3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells (2015) (4)
- SOX 4 is a direct target gene of FRA-2 and induces expression of HDAC 8 in adult T-cell leukemia / lymphoma (2013) (4)
- Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five Cases. (2020) (4)
- Incidence of carnitine deficiency in patients with cancer pain: A pilot study (2017) (4)
- Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. (2012) (4)
- Abstract 3575: The OncoNetwork Consortium: A global collaborative research study on the development and verification of an Ion AmpliSeq RNA gene lung fusion panel (2014) (4)
- Clinical outcome for EML 4-ALK-positive patients with advanced non-small-cell lung cancer treated with fi rst-line platinum-based chemotherapy (2012) (4)
- A Supramolecular Substance, [2] Rotaxane, Induces Apoptosis in Human Molt-3 Acute Lymphoblastic Leukemia Cells (2014) (4)
- Selection of surrogate marker genes in primary central nervous system lymphomas for radio-chemotherapy by DNA array analysis of gene expression profiles. (2003) (4)
- Plasma ICAM-1 (pICAM-1) and plasma IL-8 (pIL-8) level as biomarker of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV) (WJOG7612GTR). (2018) (4)
- High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib (2021) (4)
- Corrigendum: RPN2 gene confers docetaxel resistance in breast cancer (2008) (4)
- EGFR mutation in various tissues (2006) (4)
- Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer. (2021) (4)
- What can and cannot be done using a microarray analysis? Treatment stratification and clinical applications in oncology. (2011) (4)
- Effect of taxol on vinblastine sulfate-induced crystallization of tubulin. (1993) (4)
- aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer. (2018) (4)
- Correlation of FcγR IIa-H131R and IIIa-V158F polymorphisms and clinical outcome of trastuzumab in both neoadjuvant and metastatic setting in patients with HER-2 positive breast cancer. (2009) (3)
- Phorbol ester and okadaic acid-resistant cells: the crossroads of signal transduction and drug resistance. (1995) (3)
- Genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity. (2016) (3)
- Phase II/III clinical trial with VEGFR2-epitope peptide and gemcitabine for patients with locally advanced, metastatic, or unresectable pancreatic cancer: Pegasus-PC study. (2013) (3)
- Decreased expression of T‐cell‐associated immune markers predicts poor prognosis in patients with follicular lymphoma (2021) (3)
- Analysis of Cisplatin Behavior in a Non-Small Cell Lung Cancer (NSCLC) Cell Line (2006) (3)
- Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset (2021) (3)
- RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer (NSCLC). (2020) (3)
- In vitro and in vivo modulation by rhizoxin of non-P-glycoprotein-mediated vindesine resistance (2005) (3)
- Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan (2020) (3)
- Reversal of Cisplatin Resistance by the 1,4‐Benzothiazepine Derivative, JTV‐519 (2001) (3)
- Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma (2021) (3)
- Phylloid hypomelanosis associated with a mosaic trisomy 13 in the 13q31.3‐qter region: atypical phylloid distribution and typical hypomelanosis (2017) (3)
- Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial (2021) (3)
- Integrin-linked kinase pathway in heterogeneous pulmonary sarcomatoid carcinoma. (2021) (2)
- 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials (2004) (2)
- Cytoplasmic p53 aggregates accumulated in p53-mutated cancer correlate with poor prognosis (2022) (2)
- [Conquering drug resistance in lung cancer]. (2000) (2)
- PD3-1-2: Phase I trial of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with solid tumors (2007) (2)
- P3-103: Evaluation of Epidermal Growth Factor Receptor Mutation Status in Serum DNA as a Predictor of Response to Gefitinib (IRESSA) (2007) (2)
- Combination bezafibrate and nivolumab treatment of patients with advanced non–small cell lung cancer (2022) (2)
- A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L). (2021) (2)
- A randomized multicenter phase II study of FOLFIRI plus either panitumumab (Pmab) or bevacizumab (Bmab) as second-line treatment for wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) with exploratory biomarker analysis by liquid biopsy: WJOG6210G. (2016) (2)
- Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of Pten-Deficient Prostate Cancer (2021) (2)
- SY1. building the foundation for investigator-initiated clinical trial (2012) (2)
- Pharmacokinetic re-evaluation and phase I study of high dose epirubicin in advanced non-small cell lung cancer. (1993) (2)
- [Apoptosis and chemosensitivity]. (1997) (2)
- Enhancement of in vivo Antitumor Activity of a Novel Antimitotic 1‐Phenylpropenone Derivative, AM‐132, by Tumor Necrosis Factor‐cc or Interleukin‐6 (2001) (2)
- WJOG6110B (ELTOP): Randomized phase II trial comparing trastuzumab plus capecitabine (HX) and lapatinib plus capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes. (2012) (2)
- Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis (2019) (2)
- Molecular biomarker identification for esophageal adenocarcinoma using endoscopic brushing and magnified endoscopy (2020) (2)
- MRP5b/SMRP mRNA is Highly Expressed in Metallothionein-Deficient Mouse Liver (2003) (2)
- CPT‐11 Alters the Circadian Rhythm of Dihydropyrimidine Dehydrogenase mRNA in Mouse Liver (2001) (2)
- [Kinase inhibitors and their resistance]. (2015) (2)
- Correlation between epidermal growth factor receptor gene status and clinical outcome of gefitinib in Japanese patients with non-small cell lung cancer. (2006) (2)
- FGF3/FGF4 Amplification and Multiple Lung Metastases in Responders to Sorafenib in Hepatocellular Carcinoma (2013) (2)
- [Effect of cisplatin on cell cycle regulators]. (1994) (2)
- Phase II study of erlotinib plus tivantinib ( ARQ 197 ) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI , ge fi tinib or erlotinib (2016) (2)
- Activation-Induced Apoptosis of Peripheral Lymphocytes Treated with 7-Hydroxystaurosporine, UCN-01 (1999) (2)
- Abstract 4833: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutics antibody cetuximab (2012) (2)
- Genital mucosal melanoma with somatic SF3B1 R625C mutation (2018) (2)
- Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes (1996) (2)
- Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication (2021) (2)
- Novel Water-Soluble Derivatives of Docosahexaenoic Acid Increase Diacylglycerol Production Mediated by Phosphatidylcholine-Specific Phospholipase C (1993) (2)
- Performance of Idylla™ RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer (2022) (2)
- [Cell cycle regulation by anticancer agent]. (1995) (2)
- Abstract A241: Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells. (2013) (2)
- Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L). (2022) (2)
- Overcoming drug resistance in lung cancer. (1997) (2)
- A phase I and pharmacokinetic/pharmacodynamic study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in Japanese patients with solid tumor (2007) (2)
- Abstract 4: Gene amplification of EGFR, HER2, HER3 and HER4 in esophageal squamous cell carcinoma (2012) (2)
- Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy (2021) (2)
- Clinical Response to Everolimus of EGFR–Mutation‐Positive NSCLC With Primary Resistance to EGFR TKIs (2017) (2)
- Detection of EML4-ALK in serum RNA from lung cancer patients using MassARRAY platform. (2012) (2)
- The expression level of HER3 ligand heregulin mRNA as a predictive biomarker for anti-HER3 antibody patritumab combined with erlotinib in non-small cell lung cancer. (2014) (2)
- Predictive biomarker analysis of early tumor shrinkage induced by FOLFIRI+Bev for patients with metastatic colorectal cancer in WJOG4407G study. (2015) (1)
- P3.01-75 RELAY+, an Exploratory Study of Gefitinib with Ramucirumab in Untreated Patients with EGFR Mutation-Positive Metastatic NSCLC (2018) (1)
- 721 Novel Single Nucleotide Polymorphism Markers for Low Dose Aspirin-Associated Small Bowel Bleeding: A DMET Microarray Profiling Study (2014) (1)
- Multiplex genomic profiling of non-small cell lung cancer patients enrolled in the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin (WJOG6611LTR). (2014) (1)
- Heregulin as a novel cetuximab-resistace factor in colorectal cancer. (2010) (1)
- NGSCUP: Phase II trial of site-specific treatment based on gene expression and mutation profiling by next generation sequencing (NGS) for patients (pts) with cancer of unknown primary site (CUP). (2020) (1)
- [Resistance to target-based therapy and its circumvention]. (2004) (1)
- Human Breast Cancers upon Nuclear Localization of Y-Box Binding Protein-1 in Depends α Expression of HER 2 and Estrogen Receptor (2008) (1)
- Abstract 84: Functional evaluation of synchronous inactivation of PTEN and P53 in a murine model of prostate cancer (2014) (1)
- Abstract 1226: Interleukin-6 (IL-6) as a therapeutic target in prostate cancer. (2013) (1)
- 2169 Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinoma (2015) (1)
- Abstract P4-21-14: A randomized phase II trial of trastuzumab + capecitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP (2017) (1)
- Abstract 4702: PD-L1 blockade in preclinical models ofPTEN-deficient prostate cancer (2017) (1)
- Abstract 1193: DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, abrogates the resistance to T-DM1 in HER2-positive gastric cancer: a preclinical study (2017) (1)
- Preclinical Development Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib ( PF-02341066 ) in Gastric Cancer Positive for MET Ampli fi cation (2012) (1)
- [Problems associated with molecular targeted drugs for cancer]. (2006) (1)
- Lymph node metastatic melanoma from ungual melanoma: Identification of somatic mutations in KIT and LZTR1 (2018) (1)
- Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib (2014) (1)
- JNK-Mediated FOXO Expression Plays a Critical Role in EGFR Tyrosine Kinase Inhibitor-Induced BIM Expression and Apoptosis (2012) (1)
- Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer (2022) (1)
- Impact of Serum HGF on Treatment Response to EGFR Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Adenocarcinoma (2010) (1)
- Amplification of OCT4-Pseudogene POU5F1B is a Poor Prognostic Factor in Gastric Cancer (2012) (1)
- Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study) (2022) (1)
- Synergistic interactions between the synthetic retinoid tamibarotene and glucocorticoids in human myeloma cells (2009) (1)
- P3-1-64Noninvasive detection of acquired T790M mutation in NSCLC patients treated with EGFR-TKI using digital PCR of plasma (2015) (1)
- RELAY study of erlotinib (ERL) + ramucirumab (RAM) or placebo (PL) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC): Biomarker analysis using circulating tumor DNA (ctDNA) in Japanese patients (pts). (2020) (1)
- Use of amplification of the 8q24 and 20q11-13 loci to predict progression-free survival of advanced epithelial ovarian cancer patients receiving standard therapy. (2009) (1)
- Abstract 5169: Novel target molecules for treatment of cancer of unknown primary (2018) (1)
- Abstract 3629: HOXA10 expression profiles in prostate cancer (2012) (1)
- Abstract 1857: Effects of long-term chloroquine chemotherapy in a preclinical model of PTEN-deficient prostate cancer (2015) (1)
- Cytolotic activity of natural killer and lymphokine-activated killer cells against human tumor cell lines resistant to chemotherapeutic agents (1993) (1)
- [HER2 (human epidermal growth factor receptor type 2), EGFR (epidermal growth factor receptor)]. (2012) (1)
- Abstract 539: A preclinical model to evaluate the risk of increased dietary fat consumption and prostate cancer progression (2012) (1)
- RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC (2022) (1)
- The Role of DNA-Microarray in Translational Cancer Research (2005) (1)
- Abstract 3406: Impact of TJP-1 and TWIST expression on post-operative prognosis in hepatocellular carcinoma (2012) (1)
- Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report (2021) (1)
- RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Metastatic Non–Small-Cell Lung Cancer (NSCLC) (2022) (1)
- GFP image analysis in the mouse orthotopic bladder cancer model. (2008) (1)
- Phase I clinical and biomarker study of BIBF 1120, an oral multitarget tyrosine kinase inhibitor, in patients with advanced solid tumors (ST): Impact of CD133- and CD117-positive cells on a biomarker of an antiangiogenic inhibitor. (2009) (1)
- Abstract 557: Noninvasive analysis of acquired resistance to EGFR-TKI (2014) (1)
- Abstract 4699: Preclinical activity of the AKT inhibitor AZD5363 in PTEN-deficient mouse models of prostate cancer (2015) (1)
- Decreased expression of alpha2,8 sialyltransferase and increased expression of beta1,4 N-acetylgalactosaminyltransferase in gastrointestinal cancers. (2002) (1)
- BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer (2020) (1)
- Abstract 4657: MET amplification as a potential therapeutic target in gastric cancer. (2013) (1)
- Identification of prognostic biomarkers for gastric cancer by gene expression analysis (2007) (1)
- Calcitriol increases adriamycin sensitivity in human non-small cell lung cancer cells (1993) (1)
- Abstract CT215: RELAY, ramucirumab plus erlotinib (RAM+ERL) versus placebo plus erlotinib (PBO+ERL) in previously untreatedEGFRmutation-positive metastatic NSCLC: Next generation sequencing (NGS) results (2020) (1)
- [Progress of molecular targeted therapies]. (2012) (1)
- Abstract 8: A role for lumican as a biomarker of disease progression in human prostate adenocarcinoma. (2013) (1)
- Antibody-dependent cellular cytotoxicity of Cetuximab against tumor cells with wild- and mutant-EGFR (2006) (1)
- Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed (2019) (1)
- Gene expression analysis to identify the pharmacodynamic effects of docetaxel on the Rho signal pathway in human lung cancer patients (2005) (1)
- FP14.16 Phase 2 Trial of the Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer (WJOG10818L/Alt Trial) (2021) (1)
- Abstract 3864: The Jak1/2 inhibitor AZD1480 suppresses tumor growth and metastasis in genetically engineered mouse models of PTEN-deficient prostate cancer (2016) (1)
- MO4-1 EGFR inhibitor upregulates HER3 expression and enhances the efficacy of anti-HER3 antibody drug conjugate U3-1402 (2021) (1)
- The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC (2022) (1)
- 2168 Predictive biomarker analysis of early tumor shrinkage induced by FOLFIRI+Bev for patients with metastatic colorectal cancer in WJOG4407G study (2015) (1)
- A comprehensive gene mutation profiling of liquid biopsy samples from patients with gynecologic cancer by using CAPP-seq. (2018) (1)
- ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells (2022) (1)
- Abstract 3893: Overexpression of FOXQ1 is important factor in tumorigenicity and tumor growth (2010) (1)
- Abstract 3993: A microarray-based gene expression analysis identified diagnostic biomarkers for unknown primary cancer (2014) (1)
- Abstract #2671: Antitumor activity and mode of action of pentacyclic oxindole alkaloids from Uncaria tomentosa (2009) (1)
- Precision cancer genome testing needs proficiency testing involving all stakeholders (2022) (1)
- Deletional mutant EGFR detected in circulating tumor-derived DNA from lung cancer patients treated with gefitinib. (2005) (1)
- A Novel Mass Spectrometry-Based Assay for Diagnosis of EML4-ALK-Positive Non-Small-Cell Lung Cancer (2012) (1)
- PDZK1 induces resistance to apoptosis in esophageal adenocarcinoma cells (2021) (1)
- ZD6474 (ZACTIMA™), a novel inhibitor of VEGF receptor-2 tyrosine kinase, inhibits cellular growth of mesothelioma cell lines in vitro (2006) (1)
- Abstract 1731: TAK-701, a humanized monoclonal antibody to HGF, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with anEGFRmutation (2011) (1)
- in adult T-cell leukemia/lymphoma HDAC8 and induces expression of FRA-2 is a direct target gene of SOX4 (2013) (1)
- Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB 2 mutation : unusual genetics , unusual clinical course (2017) (1)
- Heterogeneity in congenital melanocytic nevi contributes to multicentric melanomagenesis. (2020) (1)
- Long-term response to ipilimumab after nivolumab failure in a case of anorectal melanoma with an intermediate tumor mutation burden and negative for PD-L1 expression. (2020) (1)
- Overexpression of FOXQ1 is Important Factor in Tumorigenecity and Tumor Growth (2012) (1)
- Antitumor Activity of Oxaliplatin, 5-FU and Paclitaxel Given Alone or in Combination with ZD1839 in Human Gastric Carcinoma Cells in vitro. (2002) (1)
- A Case of Pulmonary Tumor Thrombotic Microangiopathy Suggested by the Presence of Tumor Cells in Peripheral Blood (2020) (1)
- MO9-1 Real-world data of multiple diagnostic biomarker testing for lung cancer patients in Japan (2021) (0)
- Abstract 1856: Preclinical effects of dual AKT/MAPK inhibition in PTEN-deficient prostate cancer (2015) (0)
- Abstract 1781: Correlates of androgen deprivation and gut microbiome in mousePten-deficient prostate cancer (2021) (0)
- Abstract 370: Characterization of human umbilical vein endothelial cell clones resistant to VEGFR2 tyrosine kinase inhibitor (2010) (0)
- Abstract 3416: Androgen deprivation following JAK1/2 and PD-L1 inhibition improves antitumor efficacy in mouse models ofPten-deficient prostate cancer (2020) (0)
- Abstract 3415: Development of a new circulating tumor cell detection and isolation assay based on automated on-chip imaging flow cytometry technology (2012) (0)
- P5-06-05: Switching Addictions between HER2 and FGFR2 in HER2−Positive Breast Tumor Cells: FGFR2 as a Potential Target for Salvage after Lapatinib Failure. (2011) (0)
- Epidermal growth factor receptor mutation status in serum DNA is useful as a predictive marker of gefitinib (IRESSA) treatment (2007) (0)
- Biomarker analysis of WJOG4107, a randomized phase II trial of adjuvant chemotherapy with S-1 versus CDDP+S-1 for resected stage II-IIIA non-small cell lung cancer (NSCLC). (2013) (0)
- Abstract 3733: Heregulin as a novel resistant factor for cetuximab (2010) (0)
- P28-3 Epithelial-mesenchymal transition changes mitochondrial oxidative phosphorylation in the lung adenocarcinoma cells (2021) (0)
- Reply to A.-M. Conway et al. (2019) (0)
- MO14-1 From mouse to human: Focused gene panel immunoprofiling (2021) (0)
- Abstract 3340: Prostate cancer alters gut microbiota in mice (2020) (0)
- CORRECTION (2001) (0)
- Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing (2019) (0)
- Abstract 3951: Apalutamide reworks the immune composition of prostate tumors (2019) (0)
- Dynamics of HER3 and its correlated gene expression profile in EGFR-mutated NSCLC tumor treated with EGFR-TKI toward enhancing effectiveness of patritumab deruxtecan (HER3-DXd; U3-1402). (2022) (0)
- Cell Lung Cancer Small − Positive Non − Resistance to ALK Inhibitors in EML 4-ALK Activation of HER Family Signaling as a Mechanism of Acquired (2013) (0)
- Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501) (2022) (0)
- 259 Fibroblast growth factor 9 gene amplification can induce resistance to anti-EGFR therapy in colorectal cancer (2015) (0)
- P2.07-021 A Checkpoint Molecule B7-H3 as a Novel Immune Therapy Target for Non-Small Cell Lung Cancer (NSCLC) (2017) (0)
- Abstract 640: Exploring the relationships between prostate cancer, colorectal cancer, and ulcerative colitis (2023) (0)
- Characterization of the cytotoxic activity of [2]rotaxane (TRO-A0001), a novel supramolecular compound, in cancer cells (2016) (0)
- Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A (2017) (0)
- Abstract 5456: FGF9 gene amplification can induce resistance to anti-EGFR therapy in colorectal cancer (2015) (0)
- Difference of EGFR-Binding Wild Type and Mutant EGFR Proteins between (0)
- ESMO-JSMO joint symposium : how to integrate genome sequencing data in oncology (2014) (0)
- Abstract 1568: A2aR inhibition enhances the antitumor activity of CTLA4 blockade in mouse Pten-deficient prostate cancer (2021) (0)
- Difference of EGFR-Binding Proteins between Wild Type and Mutant EGFR (2009) (0)
- Tu1131 Molecular Biomarkers of High Risk for Cancer in Barrett's Esophagus (2016) (0)
- Abstract 5610: The multi tyrosine kinase inhibitor TAS-115 promotes innate and adaptive immune responses of androgen deprivation therapy in mouse prostate cancer (2020) (0)
- Abstract 1208: Combination effect of afatinib and BI836845, a humanized IGF ligand-neutralizing antibody, on EGFR-TKI-resistant NSCLC cells (2016) (0)
- P2-4-53EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition (2015) (0)
- Abstract 3737: Apalutamide (ARN-509) demonstrates therapeutic efficacy in genetically engineered mouse models ofPten-deficient prostate cancer (2018) (0)
- S10-1 Personalized medicine by biomarker (2008) (0)
- RASGRP 2 Suppresses Apoptosis via Inhibition of ROS Production in Vascular Endothelial Cells (2018) (0)
- Abstract 4468: Cross-species analysis and immunophenotyping using of a focused panel of immune-responsive genes (2020) (0)
- Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study) (2017) (0)
- Evolution of drug resistance in three-dimensional suspended culture platform (2017) (0)
- Antitumor effect of ZD6474 in a VEGF-producing primary gastric cancer model (2004) (0)
- Abstract 4729: Expression of lumican is negatively associated with the risk of biochemical recurrence in human prostate cancer (2014) (0)
- Gene expression and mutation profiling for cancer of unknown primary. (2017) (0)
- Abstract 916: Preclinical responses of the MEK inhibitor AZD6244 in a genetically modified mouse model of prostate cancer. (2013) (0)
- Forkhead Box Q1 Expression Is Associated With Tumor Location of Right-Sided Colon, But Not With Acquisition of Oxaliplatin Resistance in Colorectal Cancer (2021) (0)
- Tgf-β Induces Epithelial Mesenchymal Transition With Snai1 and Snai2 Up-Regulation in Human Corneal Epithelial Cells (2010) (0)
- Lines Amphotericin B in Cisplatin-resistant Human Lung Cancer Cell Modulation of Cisplatin Sensitivity and Accumulation by Updated Version (2006) (0)
- Serum levels of administered gefitinib correlate with the time to treatment failure in non small cell lung cancer patients. (2016) (0)
- O1-10-1Comparison of various EGFR tyrosine kinase inhibitors (TKIs) for tumors with exon 18 mutations of the EGFR gene (2015) (0)
- [Current Status and Future Direction of Cancer Genomic Medicine]. (2019) (0)
- Abstract 424: Amplification ofOCT4-pseudogenePOU5F1Bis a poor prognostic factor in gastric cancer (2012) (0)
- P1.02-082 The Feasibility of Cell-Free DNA Sequencing for Mutation Detection in Non–Small Cell Lung Cancer Was Determined by Tumor Volume: Topic: Other Mutations in Thoracic Malignancies (2017) (0)
- Abstract 1096: Co-targeting of AKT and Pim kinases in mousePTEN-deficient prostate cancer (2017) (0)
- Clinical significance of AR amplification from CF DNA among Japanese castration-resistant prostate cancer patients. (2019) (0)
- Abstract 2173: A multi-institutional prospective biomarker study of durvalumab after concurrent chemoradiation therapy in patients with unresectable stage III non-small cell lung cancer (WJOG11518L/SUBMARINE) (2023) (0)
- Abstract 3994: Expression levels of EGFR-ligands are up-regulated in EGFR tyrosine kinase inhibitor-resistant cell line (2010) (0)
- Implementation of clinical sequencing for molecular profiling in patients with advanced cancer. (2021) (0)
- Abstract 4825: Targeting PIM and AKT kinases impairs tumor growth and improves overall survival in a murine model of advanced castration-resistant prostate cancer (2018) (0)
- Abstract 5604: Targeting CD73 augments the efficacy of A2aR blockade in PTEN-deficient prostate cancer (2022) (0)
- 585 Enhanced sensitivity to cisplatin in high mobility group 2 (HMG2) gene-transfected cells (1997) (0)
- Abstract 653: A comparative analysis of pathological features and molecular genetics between salivary duct carcinoma and adenocarcinoma, not otherwise specified (2018) (0)
- Abstract 2868: Preclinical evaluation of the multi tyrosine kinase inhibitor TAS-115 in genetically engineered mouse models of prostate cancer (2018) (0)
- Marked response to both S-1 and pemetrexed in a patient with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinoma (2012) (0)
- Abstract 4485: Everolimus reduces androgen dependent and independent prostate cancer in the prostate specificPTENconditional gene targeting mouse model (2010) (0)
- P3.02b-120 EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib (2017) (0)
- Abstract 5023: Immunomodulation of the multi-tyrosine kinase inhibitor TAS-115 in a mouse model of prostate cancer (2019) (0)
- Correction: KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms (2022) (0)
- [Analysis of gene expression profiles in malignant brain tumors with respect to sensitivity to therapies]. (2005) (0)
- Abstract 1201: Establishment and characterization of cell lines derived from a murine model of PTEN-deficient prostate cancer (2014) (0)
- Abstract 2296: Sorafenib inhibits hepatocyte growth factor-induced epithelial mesenchymal transition in hepatocellular carcinoma (2010) (0)
- Synergistic interactions between the synthetic retinoid Tamibarotene (TM411) and Corticosteroids in human myeloma cells (2008) (0)
- Detection of epidermal growth factor receptor mutation in transbronchial aspiration cytology of non-small cell lung cancer. (2006) (0)
- Abstract 4098: Tyrosine kinase inhibitor resistance were decreased in spheroid culture platform (2017) (0)
- Biomarker Research for Development of Molecular Target Agents (2009) (0)
- Abstract 1715: Treatment-dependent effects of androgen receptor signaling suppression on immune modulation in mousePten-deficient prostate cancer (2018) (0)
- Abstract 1613: Dietary isoflavone decreases prostate cancer progression and improves survival in conditionalPten/Trp53-deficient mice (2019) (0)
- Regulation of EGFR activity through N-glycan fucosylation and effect on the sensitivity of EGFR-TKI (2007) (0)
- O3-15-2CHRONIC NICOTINE EXPOSURE MEDIATES RESISTANCE TO EGFR-TKI IN EGFR-MUTATED LUNG CANCER VIA EGFR SIGNAL (2014) (0)
- Abstract #2341: Tumor explant animal model: Moving towards tailor-made therapy of renal cell carcinoma (2009) (0)
- Abstract 1438: Acute immune responses to apalutamide in mousePten-deficient prostate cancer (2021) (0)
- Abstract 843: Increased consumption of dietary fat contributes to increased prostate cancer-specific mortality in a transgenic mouse model of prostate cancer (2011) (0)
- O1-13-4Integrative algorithm to determine the metastatic carcinoma tissue of origin using next generation sequencing (NGS) (2015) (0)
- Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer (2015) (0)
- MO37-6 Longitudinal disease monitoring with ctDNA during osimertinib treatment in EGFR T790M positive NSCLC patients (WJOG8815L) (2021) (0)
- Abstract 947: Influence of abiraterone therapy on anti-tumor immunity in genetically engineered mouse prostate cancer models (2018) (0)
- Abstract 1850: Evaluation of Pim-1 kinase inhibition in a preclinical model of mouse prostate cancer (2015) (0)
- 222 17-AAG, an inhibitor of HSP90, suppresses cellular growth of mesothelioma cell lines in vitro (2006) (0)
- Abstract 5282: Preclinical efficacy of abiraterone plus capivasertib in mouse Pten-deficient prostate cancer (2022) (0)
- Abstract. Patients with non-small cell lung cancer (NSCLC) with echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangements (2014) (0)
- Abstract 4996: A real-time PCR-based approach to quantitatively assess tumor immune profiles and immune responses (2019) (0)
- DEVELOPMENT OF STRATEGIES FOR NON-SURGICAL TREATMENT IN PANCREATIC CANCER (2007) (0)
- Abstract 613: Combining PI3K and 5alpha-reductase inhibitors improves the treatment response in a mouse model of PTEN-deficient prostate cancer (2014) (0)
- Abstract 3424: Slug-mediated epithelial mesenchymal transition in lung cancer cells (2011) (0)
- Abstract 5637: Transformation of the gut microbiome in response to androgen deprivation and the transition to castration-resistant prostate cancer (2022) (0)
- Abstract 4439: Genetic alterations in specific RNA processing genes is associated with poor patient outcome in prostate cancer (2018) (0)
- Abstract 1582: Therapeutic potential of combination therapy using a next generation antisense oligonucleotide targeting the androgen receptor and AKT inhibition with AZD5363 in genetically engineered mouse models of prostate cancer (2017) (0)
- Efficacy of Crizotinib after Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged Non–Small Cell Lung Cancer: Case Report (2023) (0)
- Abstract 1780: Associations between gut microbiota and PD-L1 immunotherapy/JAK1/2 inhibition in mousePten-deficient prostate cancer (2021) (0)
- Antitumor activity of TZT-1027 against cytokine-gene-transfected Lewis lung carcinomas inoculated to C57BL/6 mice (2000) (0)
- Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis. (2022) (0)
- Abstract 433: Altered expression of lumican in prostate cancer is identified by microarray analysis (2011) (0)
- [Biomarker research for a clinical setting]. (2012) (0)
- O3–053ORAOV1 IS AMPLIFIED IN ESOPHAGEAL SQUAMOUS CELL CANCER AND RELATED TO TUMOR GROWTH AND POORLY DIFFERENTIATED TUMOR (2013) (0)
- Abstract 1147: microRNA expression profiling in cisplatin resistant human non-small cell lung cancer cell lines (2011) (0)
- Slug Is Upregulated During Wound Healing And Downregulates Tp63 In Corneal Epithelial Cells (2011) (0)
- IS6-5PHASE I STUDY OF YM155, SELECTIVE SURVIVIN SUPPRESSANT PLUS ERLOTINIB IN PATIENTS WITH EGFR-MUTANT ADVANCED NSCLC (2014) (0)
- Abstract 2167: Identification of aberrant expression of HOXA10 in prostate cancer (2011) (0)
- 145INNEW INSIGHTS FOR SEQUENCING DATA IN LUNG CANCER. (2014) (0)
- P3.01-45 Multifactorial Gene Alterations in EGFR Bypass Pathway are Induced by Afatinib in T790M-Mutant NSCLC Resistant to Osmertinib (2018) (0)
- Antitum or Activity of O xaliplatin, 5-FU and Paclitaxel G iven Alone or in Com bination with ZD 1839 in H um an Gastric Carcinom a Cells in vitro (2003) (0)
- O9-2 Comprehensive gene mutation profiling of ctDNA in ovarian cancer and its pathological and prognostic impact (2021) (0)
- Abstract 4315: Effects of increased dietary fat consumption on prostate cancer progression in genetically engineered mice (2016) (0)
- PD3-3-2: A randomized double-blind Phase IIa dose-finding study of vandetanib in Japanese patients with NSCLC (2007) (0)
- 3016 Receptor tyrosine kinase mutations in non-small cell lung cancer (2015) (0)
- Development and characterization of an antibody specifically recognizing a mutant EGFR (L858R) protein expressed frequently in non-small cell lung cancer (2006) (0)
- 104 CDH2 negative esophageal squamous cell carcinoma with cytotoxic T-lymphocyte signatures is a good responder subtype to definitive chemoradiotherapy (2015) (0)
- Amplification MET ( PF-02341066 ) in Gastric Cancer Positive for Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (2013) (0)
- Abstract 5211: Therapeutic resistance to anti-AR signal pathway therapies is related to compensatory pathway activation and immune suppression in mouse Pten/Trp53-deficient CRPC (2022) (0)
- O1-9-6A prospective biomarker study in afatinib-treated patients with EGFR-mutation positive non-small cell lung cancer (2015) (0)
- Abstract 1840: Contribution of miR-205 in gefitinib-resistant lung cancer cell lines (2014) (0)
- Abstract 3912: The role of autophagy in prostate tumorigenesis and its therapeutic implications (2014) (0)
- Application of Flow Cytometry to Translational Study of Target-based Therapy (2004) (0)
- A Pilot Proficiency Testing Study for Assessing Cancer Gene Panel using Patient Samples and Next-generation Sequencing in Japan (2021) (0)
- Abstract 3371: Expression levels of EMT-related genes in hepatocellular carcinoma (2011) (0)
- Abstract 5246: Use of near infrared fluorescence imaging to determine tumor burden in genetically engineered mice (2010) (0)
- act of Serum Hepatocyte Growth Factor on Treatment ponse to Epidermal Growth Factor Receptor Tyrosine ase Inhibitors in Patients with Non–Small Cell (2010) (0)
- Abstract 4533: Characteristics of HS6ST2 expression in colorectal cancer (2012) (0)
- [Molecular diagnostic methods designed for clinical approach to cancer of unknown origin]. (2009) (0)
- Abstract 3986: Digital droplet PCR measurement for plasmaHER2amplification in patients with AGC (2019) (0)
- Plasma VEGF-A (pVEGF-A) level in efficacy analysis of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV) (WJOG7612GTR). (2018) (0)
- Drug Accumulation and Efflux Do not Contribute to Acquired Gefitinib Resistance (2009) (0)
- Abstract 3402: Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer (2015) (0)
- Abstract 6143: Tumor immune microenvironment in salivary gland cancer (2022) (0)
- A cationic liposomal gene delivery system with adenoviral DNA-terminal protein complex (2000) (0)
- Phase II study of osimertinib in patients with plasma EGFR T790M positive advanced lung cancer (WJOG8815L/LPS). (2018) (0)
- Cisplatin sensitivity and resistance in lung cancer (1998) (0)
- Transcriptional expression of Bcl-2 as predictive of response to neoadjuvant chemotherapy with trastuzumab in HER2-positive ER-positive breast cancer patients. (2014) (0)
- O1-9-2TUMOR GENOMIC PROFILING OF NSCLC FROM THE PHASE III TRIAL OF FIRST-LINE S-1/CBDCA VERSUS PACLITAXEL/CBDCA (WJOG6611LTR) (2014) (0)
- Abstract 622: Gene panel-based immune profiling of human cancers (2021) (0)
- Decreased Expression of T-Cell-Associated Immune Markers Predicts Poor Prognosis in Patients with Advanced Follicular Lymphoma Received Rituximab Plus Bendamustine (2021) (0)
- Activin-A Directly Inhibits Vascular Endothelial Cell Growth VIA TGF-b-Dependent Signal Pathway (2012) (0)
- Progress in the field of molecular biology and application of biotechnology to medical oncology (2006) (0)
- Abstract 5207: FGFR inhibitor regulates CD133 expression in FGFR2-amplified gastric cancer cells (2011) (0)
- Corrigendum: Curcumin β-D-Glucuronide Modulates an Autoimmune Model of Multiple Sclerosis with Altered Gut Microbiota in the Ileum and Feces (2022) (0)
- MO29-5 RELAY+: Exploratory study of RAM+GEF in untreated patients with EGFR M+ NSCLC: Updates on efficacy, safety and biomarker (2021) (0)
- Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas. (2021) (0)
- O3–096BIOMARKER ANALYSIS OF WJOG4107 (A RANDOMIZED PHASE II TRIAL OF ADJUVANT CHEMOTHERAPY WITH S-1 VS CDDP + S-1 IN NSCLC) (2013) (0)
- Upregulated gene expression of angiogenesis factors in post-chemotherapeutic resected lung cancer tissues determined by cDNA macroarray (2000) (0)
- [Tubulin and its related signal]. (1997) (0)
- Phase I study of docetaxel (DTX) and carboplatin (CBDCA) in advanced non-small cell lung cancer (NSCLC) (2000) (0)
- WS1. the expansion of surgical indication in gastric colorectal cancer drug therapy (2012) (0)
- Abstract 1099: Aza-derivatives of resveratrol are potent inhibitors of macrophage migration inhibitory factor (MIF) (2011) (0)
- 2152 Exploratory analysis of predictive biomarkers of oxaliplatin versus irinotecan in combination with bevacizumab for patients with metastatic colorectal cancer in WJOG4407G study (2015) (0)
- [Genomic Analysis-Based Treatment for Cancer of Unknown Primary]. (2022) (0)
- 484PDA multicenter prospective biomarker study in afatinib-treated patients with EGFR-mutation positive non-small cell lung cancer (2015) (0)
- Reversal of cisplatin-resistance by 1,4-benzothiazepin derivative, JTV-519 (2000) (0)
- Abstract 4958: Melanoma transition is frequently accompanied by a loss of cytoglobin, a putative tumor suppressor, in melanocytes (2015) (0)
- Characteristics of HS6ST2 Expression in Colorectal Cancer (2012) (0)
- [PI3K and mTOR pathway and molecular targeted agents]. (2015) (0)
- P3.01-96 Clinical Characteristics of Non–Small Cell Lung Cancer Harboring Mutations in Exon 20 Of EGFR or HER2 (2018) (0)
- O-6 Gene alterations in ctDNA related to the resistance mechanism of anti-EGFR antibodies and clinical efficacy outcomes of anti-EGFR antibody rechallenge plus trifluridine/tipiracil in metastatic colorectal cancer patients in WJOG8916G trial (2021) (0)
- Abstract 3341: Systemic targeted JAK1/2 therapy for mousePten-deficient prostate cancer model influences the diversity and composition of the gut microbiome (2020) (0)
- Abstract 611: Co-targeting the PI3K and androgen receptor signal pathways in castration resistant prostate cancer (2014) (0)
- Enhancement of Epidermal Growth Factor Receptor-degradation Pathway in Acquired Gefitinib-resistant Human Non-small Cell Lung Cancer Cell Lines (2004) (0)
- Elucidation of the gefitinib (‘Iressa’, ZD1839)-resistant mechanisms in acquired gefitinib-resistant human non-small-cell lung cancer cell lines (2004) (0)
- Abstract P2-05-24: Prognostic value of circulatingPIK3CAmutations revealed with digital PCR in patients with HER2-positive advanced breast cancer: Results of West Japan Oncology Group study 6110BTR (2017) (0)
- Abstract 3688: Leptin contributes to prostate cancer progression. (2013) (0)
- Correction. (2016) (0)
- Abstract 3542: Analysis of miRNA mediated Cisplatin resistant mechanisms (2010) (0)
- Abstract 4212: Inhibition of mouse PTEN-deficient prostate cancer with next generation antisense oligonucleotide targeting the androgen receptor (2015) (0)
- Abstract 3876: Role of Stat3 transcriptional activation in a preclinical mouse model of prostate cancer and potential as a therapeutic target (2012) (0)
- Tgf-β Regulates Proliferation and Emt-Related Gene Expression of Human Corneal Epithelial Cell (2009) (0)
- Abstract 956: Targeting prostate cancer chemoprevention via the androgen receptor in a preclinical mouse model (2010) (0)
- Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study (2018) (0)
- Cancer Biology and Signal Transduction MEK Inhibitor for Gastric Cancer with MEK 1 Gene Mutations (2014) (0)
- Abstract 906: Therapeutic potential of JAK/STAT signal inhibition in prostate cancer by the JAK inhibitor AZD1480. (2013) (0)
- [Chemosensitivity test for lung cancer]. (1990) (0)
- Effect of suramin on cdc2 kinase activity of the purified enzyme and from the crude extracts from lung cancer cells (1994) (0)
- 556 Ectopic p16INK4 expression enhances the susceptibility of human non-small cell lung cancer (NSCLC) cells to CPT-11-induced apoptosis (1997) (0)
- Contents Vol. 34, 2016 (2016) (0)
- Phase I study of YM155, selective survivin suppressant in combination with elrotnib in patients with EGFR-mutant advanced non-small cell lung cancer. (2016) (0)
- Real-world study of next-generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan. (2023) (0)
- Abstract 2755: Enhanced anti-tumor effects using a combinatorial targeted treatment strategy in a preclinical model of prostate cancer (2012) (0)
- Multiplexed Diagnostics for Precision Medicine in Lung Cancer (2016) (0)
- Abstract 1095: Short Poly A sequence in HGF promoter region is involved in overexpression of HGF in cancer cells (2011) (0)
- The development of a treatment model for lymph node metastasis in nude mice transplanted with rat fibrosarcoma clone A. (1991) (0)
- P3.02b-026 Association of EGFR Exon 19 Deletion and EGFR-TKI treatment duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients: Topic: EGFR Biomarkers (2017) (0)
- Abstract 3579: Sorafenib inhibits tumor development and growth in a transgenic mouse model of prostate cancer (2011) (0)
- Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study). (2022) (0)
- Abstract 4446: Activation of HER Family signaling as a mechanism of acquired resistance to ALK Inhibitors in EML4-ALK-positive Non-Small Cell Lung Cancer. (2013) (0)
- Activation of ERK1/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukaemia cells. (2023) (0)
- Abstract 954: Analysis of noncoding RNA expression in a mouse model of PTEN-deficient prostate cancer (2016) (0)
- Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period (2021) (0)
- HER3 ligand heregulin expression and clinical implication in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors (2019) (0)
- O2-15-3MEK INHIBITORS ARE EFFECTIVE AGAINST GASTRIC CANCER CELL LINES WITH ONCOGENIC MEK1 GENE MUTATIONS (2014) (0)
- MA08.08 Implementation of Diagnostic Biomarker Testing in Lung Cancer: Real-World Data in Japan (2021) (0)
- Abstract 4891: Comprehensive genetic profiling of chromosomal translocations in lung cancer tumors: development and validation of a next-generation sequencing panel in an international multicenter study (2015) (0)
- Abstract 1844: Novel HER3 neutralizing antibody, patritumab abrogates cetuximab resistance mediated by a heregulin-autocrine loop in colorectal cancer (2014) (0)
- Abstract 5952: Curcumin monoglucuronide modulates the tumor microenvironment of Pten-null prostate tumors and exhibits antitumor activity (2022) (0)
- Abstract 4185: Serum concentrations of angiogenesis-related molecules in patients with pancreatic cancer (2011) (0)
- Abstract 3044: Integrative gut microbiome analysis of human and mouse prostate cancer (2023) (0)
- An analysis of serum heparan sulfate concentration and EGFR tyrosine kinase inhibitor treatment in patients with non-small cell lung adenocarcinoma. (2011) (0)
- OS1. gastric cancer (2012) (0)
- P1–160CONSTRUCTION OF A 3D CULTURE ASSAY SYSTEM FOR ANTI-CANCER DRUG TESTING (2013) (0)
- Genetic Pro fi ling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA (2019) (0)
- O3-1 A phase II study on the efficacy of nivolumab in patients with cancer of unknown primary (CUP) (NivoCUP) (2021) (0)
- Precision cancer genome testing needs proficiency testing involving all stakeholders (2022) (0)
- MIS2. lung cancer clinical (2012) (0)
- Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib (2020) (0)
- Predictive value of serum HGF for treatment response to EGFR tyrosine kinase inhibitor in patients with lung adenocarcinoma. (2010) (0)
- Abstract 5155: Targeting tumor infiltrating myeloid cells in prostate cancer (2023) (0)
- Abstract 751: Characterization of STAT3 activation in human prostate cancer (2017) (0)
- Cure of Cancer (1896) (0)
- O1–057COMT GENOTYPE AND PATIENTS' RECOGNITION OF PAIN REDUCTION ARE PREDICTIVE MARKERS FOR THE RESPONSE TO MORPHINE TREATMENT (2013) (0)
- Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer (2014) (0)
- Abstract 1893: The effect of kinase signaling for miR-205 regulation in gefitinib-resistant lung cancer cell lines (2016) (0)
- Potential research and clinical utility of liquid biopsy with CAPP seq. (2018) (0)
- Abstract 5178: Evaluation of lumican expression profiles in prostate cancer (2012) (0)
- [CDK inhibitors for therapy of cancer]. (2001) (0)
- Abstract 3061: Somatic mutation profiling to tumor samples using OncoCarta Panel (2011) (0)
- Multi-probe droplet digital PCR increased the detection efficiency of plasma EGFR exon 19 deletion mutation. (2017) (0)
- Abstract 3313: Snail and slug-mediated epithelial mesenchymal transition in lung cancer cells (2010) (0)
- P2.14-15 Impact of Coexisting Gene Mutations in EGFR-Mutated Non–Small Cell Lung Cancer Before Treatment on EGFR T790M Mutation Status After EGFR-TKIs (2019) (0)
- Abstract 1845: Chloroquine demonstrates limited effectiveness in an autochthonous preclinical model of prostate cancer (2015) (0)
- MA08.10 Detection of the T790M Mutation of EGFR in Plasma of Advanced NSCLC Patients with Acquired Resistance to EGFR-TKI (WJOG8014LTR) (2017) (0)
- [Clinical Application of NGS-Based Clinical Sequencing]. (2017) (0)
- Abstract 2014: Alternative splicing is a frequent event in mouse PTEN-deficient prostate cancer (2016) (0)
- The Liquid Biopsy: Its Present and Future (2017) (0)
- Genetic variants of cancer‑associated genes analyzed using next‑generation sequencing in small sporadic vestibular schwannomas. (2023) (0)
- Improved mouse orthotopic bladder cancer model quantification using GFP image analysis (2007) (0)
- Abstract 2052: Tumor mutation burden as a biomarker of relapse free survival of non-squamous non-small cell lung cancer treated with PEM/CDDP in adjuvant setting (the JIPANG-TR) (2020) (0)
- Abstract 3538: Effects of oral chloroquine administration on a preclinical mouse model of PTEN/p53-deficient prostate cancer (2016) (0)
- Abstract 2156: Integration of whole genome exon array and array CGH analysis in gastric and colorectal cancer cell lines (2010) (0)
- MO2-2 Preclinical evaluation of androgen deprivation with JAK1/2 and PD-L1 inhibition in mouse Pten-deficient prostate cancer (2021) (0)
- [gamma-Glutamylcysteine synthetase and chemosensitivity]. (1997) (0)
- A phase II study on the efficacy of Nivolumab in Japanese patients with cancer of unknown primary (CUP) (NivoCUP). (2018) (0)
- 329PAfatinib activity against head-and-neck or esophageal squamous cell carcinoma: Significance of activating oncogenic HER4 mutations in head-and-neck squamous cell carcinoma (2015) (0)
- Abstract 1209: Detection of EGFR T790M mutation in non-small-cell lung cancer patients using colony hybridization assay (2012) (0)
- Abstract 1071: Targeting A2aR in mousePten-deficient prostate cancer (2020) (0)
- Relationship between checkpoint molecule B7-H3 and refractoriness to anti-PD-1 therapy in non-small cell lung cancer. (2018) (0)
- Recommendations related to the analytical equivalence assessment of gene panel testing (2022) (0)
- Abstract 3818: Identification of aFGFR3-TACC3fusion in esophageal cancer (2017) (0)
- Title Ciliated muconodular papillary tumors of the lung withKRAS / BRAF / AKT 1 mutation (2019) (0)
- Abstract A146: Meloxicam inhibits prostate tumor growth and progression in prostate specific‐PTEN conditional gene targeting knockout mice (2010) (0)
- Uterine angioleiomyoma with disseminated intravascular coagulation: a case report (2023) (0)
- Phase I dose escalation study of E7080, a novel anti-angiogenic multikinase inhibitor, in Japanese patients with advanced solid tumors (2007) (0)
- Detection of Epidermal Growth Factor Receptor Mutations in Serum DNA Using the Scorpion ARMS in Patients with Advanced Non-Small-Cell Lung Cancer (2007) (0)
- Abstract 4608: Autophagy is required for prostate cancer progression. (2013) (0)
- Evaluation of a Novel Flow Cytometry-Based System for the Detection of Circulating Tumor Cells (2012) (0)
- Identification pharmacogenomic markers for predicting paclitaxel-related toxicity in breast cancer patients treated with neoadjuvant chemotherapy (2005) (0)
- CPT-11 shifts a circadian rhythm of dihydropyrimidine dehydrogenase mRNA in mouse liver (2000) (0)
- Next-generation sequencing–based clinical testing for lung cancer in Japan (2017) (0)
- Su1951 Over Expression of Cd55 and Loss of Dsc2 From Barrett's Columnar-Lined Esophagus Are Associated With Esophageal Adenocarcinoma Risk (2013) (0)
- METex14 Skipping Testing Guidance for Lung Cancer Patients: The Guidance from the Biomarker Committee, the Japan Lung Cancer Society (2021) (0)
- O3-15-3HEREGULIN AS A BIOMARKER FOR ANTI-HER3 ANTIBODY PATRITUMAB COMBINED WITH ERLOTINIB IN NON-SMALL CELL LUNG CANCER (2014) (0)
- P2.13-18 A Multicenter Prospective Biomarker Study to Explore Mechanisms of Afatinib Resistance Based on Digita PCR and Next-Generation Sequencing (2018) (0)
- Present state and prospects of measurement technologies for analysis of circulating tumor cell (2011) (0)
- P-247 FLOW CYTOMETRIC MONITORING OF CELLULAR DOXORUBICIN RETENTlON AND ITS HETEROGENEITY IN DRUG RESISTANT HUMAN LUNG CANCER CELL LINES (1992) (0)
- Signal Transduction and Drug Sensitivity (2006) (0)
- Tokuda Akihiro Tomida Shinya Toyokuni Hitoshi Tsuda Shoichiro Tsugane Tatsuhiko Tsunoda Heiichiro Udono Koji Ueda Yoshimasa Uehara Hiroo Ueno Kazuo Umezawa Toshikazu Ushijima Toshihiko Wakabayashi Kenji Wakai Tetsuro Watabe (2016) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Kazuto Nishio?
Kazuto Nishio is affiliated with the following schools:
